AlphaCentric Advisors’s Collegium Pharmaceutical COLL Stock Holding History

AlphaCentric Advisors’s Portfolio COLL Stock Details COLL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-49,500	Closed	-$1.11M	–	239
2023 Q3	$1.11M	Hold	49,500	–	–	0.63%	55
2023 Q2	$1.06M	Hold	49,500	–	–	0.59%	66
2023 Q1	$1.19M	Hold	49,500	–	–	0.82%	36
2022 Q4	$1.15M	Sell	49,500 -19,000	-28%	-$383K	1.13%	26
2022 Q3	$1.1M	Buy	+68,500	New	+$1.21M	1.13%	21
2021 Q4	$1.13M	Buy	60,500 +23,500	+64%	+$458K	0.33%	26
2021 Q3	$730K	Buy	37,000 +28,000	+311%	+$605K	0.19%	51
2021 Q2	$213K	Hold	9,000	–	–	0.06%	104
2021 Q1	$213K	Hold	9,000	–	–	0.07%	92
2020 Q4	$180K	Buy	9,000 +6,600	+275%	+$129K	0.08%	73
2020 Q3	$50K	Sell	2,400 -750	-24%	-$13.5K	0.02%	106
2020 Q2	$55K	Buy	+3,150	New	+$61.7K	0.03%	81

Other funds holding COLL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaCentric Advisors's COLL Position: Q4 2023 in Review

AlphaCentric Advisors sold out of Collegium Pharmaceutical (COLL) in Q4 2023, closing a stake of 49,500 shares — an estimated $1.11M sold.

AlphaCentric Advisors first reported a position in COLL in Q2 2020 and held it in 12 quarters. The position peaked at $1.19M in Q1 2023. 193 funds tracked by Wall St. Rank hold COLL as of Q4 2023.

AlphaCentric Advisors reported no remaining Collegium Pharmaceutical position as of Q4 2023 after selling out during the quarter.
AlphaCentric Advisors sold 49,500 Collegium Pharmaceutical shares in Q4 2023, an estimated $1.11M.
AlphaCentric Advisors first reported a position in Collegium Pharmaceutical in Q2 2020 and held it in 12 quarters.
AlphaCentric Advisors's Collegium Pharmaceutical position peaked at $1.19M in Q1 2023.
193 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2023.

Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.